#USA #Princeton #Syenex #T Cell Therapy #Made Scientific

A Transformative Alliance in Cell Therapy Manufacturing

In a significant move that stands to reshape the future of T cell therapies, Made Scientific, a well-known contract development and manufacturing organization (CDMO), has embarked on a pioneering partnership with Syenex, a synthetic biology firm acclaimed for its groundbreaking targeted delivery technologies. This new alliance, announced on September 30, 2025, aims to drastically improve the scalability and efficiency in the manufacturing of engineered T cell therapies.

At the core of this collaboration lies Syenex's advanced bioengineering systems: UltraCell™ and RapidCell™. These systems promise a remarkable up to 10-fold improvement in the efficiency of gene delivery while also significantly shortening manufacturing timelines. Perhaps most intriguingly, they stand to reduce production costs through superior delivery vector engineering. As the need for more accessible and cost-effective therapies grows, this partnership could not have come at a more pivotal time for the healthcare landscape.

During their initial collaborative study, Made Scientific and Syenex have successfully demonstrated the capabilities of the RapidCell™ system. Notably, this system serves as a cost-efficient and effective alternative to conventional transduction and activation reagents that typically dominate the industry. Early data indicates that RapidCell™ also excels in its specificity, allowing for the transduction and activation of non-enriched cell populations. This breakthrough could revolutionize the manufacturing process, making it more streamlined and economically viable than ever before.

Excitement surrounds the potential outcomes of this partnership, as results from their proof-of-concept trials are expected to be unveiled at an upcoming forum. With plans to incorporate this innovative technology into a customer-accessible manufacturing platform by 2026, both organizations are on the cusp of potentially transformative advancements in healthcare.

Syed T. Husain, Chairman and CEO of Made Scientific, expressed enthusiasm regarding this new venture, stating, "We look forward to collaborating with Syenex to tackle the critical challenges of scalability, cost, and efficiency in cell therapy manufacturing. By synergizing our strengths, we are enabling a more efficient platform that therapeutic developers can utilize, thereby accelerating the journey from research and development to good manufacturing practice (GMP) and ultimately making life-saving therapies more accessible to patients in need."

Syenex's Co-Founder and CEO, Jay Rosanelli, echoed the optimism, highlighting the potential of their UltraCell™ and RapidCell™ systems to redefine the landscape of T cell therapy manufacturing. He remarked, "Our collaboration aims to demonstrate how advanced delivery engineering can obliterate scalability and cost barriers, ultimately speeding up the process from concept to clinically applicable solutions that can save lives."

This partnership represents a critical milestone in the cell therapy arena, positioning Made Scientific and Syenex not just as industry participants but as leaders in the quest for innovative solutions to longstanding challenges in healthcare. They are poised to become pivotal players in the development of next-generation T cell therapies, thereby ensuring that life-saving treatments will reach patients with increasing speed and impact.

About Made Scientific

Made Scientific operates as a leading U.S.-based CDMO, specializing in both autologous and allogeneic cell therapy product development and manufacturing. With two primary manufacturing facilities in the United States, the company blends agility with the extensive expertise of GC Corporation, a major player in the pharmaceutical and biotechnology sectors.

About Syenex

Founded in 2022, Syenex has established itself as a premier biotechnology platform, emphasizing precision and scalability in programming cells. With over 50 partnerships in biopharma and academia, Syenex is leveraging synthetic biology to create dynamic delivery systems that facilitate quick advances from the laboratory to clinical applications.

As the healthcare landscape evolves, the collaboration between Made Scientific and Syenex heralds a promising future, one where advanced, efficient, and cost-effective cell therapies are within reach for patients who need them most.